BEST – Biomarker evaluation to support clinical translation for schizophrenia

Psychoses are a group of disorders of extraordinary heterogeneity.

Beschreibung

Psychoses describe an extremely heterogeneous group of diseases. As a result, diagnoses, prognoses and treatment decisions for individual patients are challenging. Within the project, biomarker signatures of patients at high risk of schizophrenia and patients with defined psychotic disorders will be optimized. This will be investigated by integrating multimodal patient data and subsequent functional validation of biomarker signatures using patient derived neurons.

 

Partner:

Period:
01.09.2021 - 31.08.2024
FKZ:
01EK2101A
Funding:
Bundesministerium für Bildung und Forschung (BMBF)
Management:
Deutsches Zentrum für Luft- und Raumfahrt (DLR)

Projectlead

Prof. Dr. Hansjürgen Volkmer

Head of Pharma & Biotech

+49 7121 51530-44
Contact via email
Show CV

NMI Natural and Medical Sciences Institute
at the University of Tübingen
Markwiesenstraße 55, 72770 Reutlingen
Tel.: +49 7121 51530-0
Mail: info@nmi.de

Follow us now

Subsidiary company
Member of
Member of